(Q38457735)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

review article

6 references

25 July 2020

20 September 2020

4 December 2020

26 January 2021

1 May 2021

Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

5 references

25 July 2020

20 September 2020

4 December 2020

26 January 2021

1 May 2021

chemical synaptic transmission

2 references

25 July 2020

4 December 2020

neuroprotective agent

1 reference

26 January 2021

sodium channel blocker

1 reference

1 May 2021

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Narihito Nagoshi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Hiroaki Nakashima

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

29 April 2015

6 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

25 July 2020

20 September 2020

4 December 2020

26 January 2021

1 May 2021

6 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

25 July 2020

20 September 2020

4 December 2020

26 January 2021

1 May 2021

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

7775-7789

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

7 March 2020

copyright license

5 references

25 July 2020

20 September 2020

4 December 2020

26 January 2021

1 May 2021

0 references

Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS)

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Rehabilitation in spine and spinal cord trauma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Riluzole, a glutamate release inhibitor, and motor behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Na(+)-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Calcium Dependence of Toxic Cell Death: A Final Common Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Excitatory amino acids as a final common pathway for neurologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Cytokine-induced acute inflammation in the brain and spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Effect of intravenous lidocaine on experimental spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

North American Clinical Trials Network for the Treatment of Spinal Cord Injury: goals and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Incidence and severity of acute complications after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Spinal cord injury sequelae alter drug pharmacokinetics: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

L-arginine reverses alterations in drug disposition induced by spinal cord injury by increasing hepatic blood flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Early versus late surgery for traumatic spinal cord injury: the results of a prospective Canadian cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

Pharmacology of riluzole in acute spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES20057775

A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers

21 January 2018

1 reference

12 December 2020

Effects of the sodium channel blocker tetrodotoxin on acute white matter pathology after experimental contusive spinal cord injury.

1 reference

12 December 2020

Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport.

1 reference

12 December 2020

Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury

1 reference

12 December 2020

Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole.

1 reference

12 December 2020

Dependence of hypoxic cellular calcium loading on Na(+)-Ca2+ exchange

1 reference

12 December 2020

Antinociceptive effect of riluzole in rats with neuropathic spinal cord injury pain

1 reference

12 December 2020

Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from Phase I to II.

1 reference

12 December 2020

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

12 December 2020

Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+, Na(+)-K(+)-ATPase, the Na(+)-H+ exchanger, and the Na(+)-Ca2+ exchanger.

1 reference

12 December 2020

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

12 December 2020

The effect of riluzole on post-traumatic spinal cord injury in the rat.

1 reference

12 December 2020

Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury.

1 reference

12 December 2020

International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of riluzole in white subjects

1 reference

12 December 2020

10.3390/MOLECULES20057775

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

release_abvv4jzuuzgfvl3vxjrx6mga64

7 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/abvv4jzuuzgfvl3vxjrx6mga64

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25939067%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

25939067

1 reference